The Manufacturers Life Insurance Company acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 658,659 shares of the company's stock, valued at approximately $31,135,000. The Manufacturers Life Insurance Company owned 1.39% of Prestige Consumer Healthcare as of its most recent SEC filing.
Several other large investors have also bought and sold shares of PBH. UMB Bank n.a. increased its stake in shares of Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company's stock valued at $26,000 after buying an additional 219 shares during the period. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Prestige Consumer Healthcare in the second quarter worth approximately $30,000. Versant Capital Management Inc boosted its holdings in Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company's stock valued at $34,000 after acquiring an additional 235 shares during the last quarter. Torren Management LLC bought a new stake in Prestige Consumer Healthcare in the fourth quarter valued at approximately $35,000. Finally, Caitong International Asset Management Co. Ltd increased its position in Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock valued at $35,000 after purchasing an additional 236 shares during the period. 99.95% of the stock is owned by institutional investors.
Prestige Consumer Healthcare Price Performance
Shares of NYSE:PBH opened at $51.27 on Friday. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $71.07. The stock's 50 day moving average is $50.11 and its 200-day moving average is $54.64. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 1.63 and a beta of 0.34.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. The business had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. Prestige Consumer Healthcare's revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on PBH. Canaccord Genuity Group lowered their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a report on Friday, May 15th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, June 25th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research report on Monday, August 10th. Finally, Oppenheimer downgraded shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $70.75.
Check Out Our Latest Stock Report on PBH
Prestige Consumer Healthcare News Summary
Here are the key news stories impacting Prestige Consumer Healthcare this week:
- Positive Sentiment: Zacks projects earnings growth from $4.55 per share in FY2027 to $5.06 in FY2028 and $5.25 in FY2029, implying continued profit expansion for Prestige Consumer Healthcare.
- Neutral Sentiment: The firm estimates quarterly EPS of $1.06 for Q2 FY2027, $1.22 for Q3, and $1.30 for Q4. Its FY2027 forecast of $4.55 is broadly aligned with the current $4.56 consensus estimate.
- Neutral Sentiment: Zacks maintained a “Hold” rating on PBH, signaling limited conviction that the projected earnings growth currently warrants a more bullish stance. Prestige Consumer Healthcare analyst estimates
- Negative Sentiment: The update consists primarily of routine estimates for periods extending through FY2029, rather than a fresh earnings beat, guidance increase, or strategic announcement. That lack of a new positive catalyst may be weighing on the stock in the near term.
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.
Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
